API pharmaceutical company Asymchem revealed on Wednesday the addition of Scott A. May to its board of scientific advisers (BSA).
The company added Dr May joins Professors Barry Sharpless, Phil Baran, Stephen Buchwald and other members on the advisory board.
Established in June 2013, the BSA consists of 11 academic and industry technical leaders to provide valuable advice on research targets as well up-to-date technologies with potential applications into the CDMO space. Collaborative research opportunities have continued to yield publications in JOC, JACS, OPRD, Science and others.
Previously, Dr May was a senior organic chemist of Process Research group at Eli Lilly and the research fellow in the Small Molecule Design and Development group.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval